Clinical Trial

Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics…

8 months ago

UNITY Biotechnology Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME

SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing…

8 months ago

Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections

Human Research Ethics Committee (HREC) approval received to allow up to 20 additional patients access to RECCE® 327 Topical Gel…

8 months ago

NanoDrops Names Daria Lemann-Blumenthal as CEO

Lemann-Blumenthal, an experienced business leader in the ophthalmic technology space, led her previous company to acquisition by global eye care…

8 months ago

UCSF Expands Arrhythmia Research with Vivalink’s Biometrics Data Platform in Study to Examine Arrhythmias in High-Risk Pregnancies

BRITE-MOM study uses Vivalink's wearable devices and data platform to examine arrhythmias in high-risk pregnancies CAMPBELL, Calif., April 22, 2025…

8 months ago

Lumenis Unveils Enhanced SPLENDOR X™ Laser Hair Removal Solution with New Clinical Data at the Annual American Society for Laser Medicine and Surgery (ASLMS) Conference

New data demonstrates effectiveness of SPLENDOR X™'s dual-wavelength simultaneous laser emission technology for improved hair removal resultsThe newest editions of…

8 months ago

PathAI Announces Poster Presentations at the 2025 American Association of Cancer Research Annual Meeting

BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in AI-powered pathology solutions, today announced it will present…

8 months ago

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in…

8 months ago

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

Nes-Ziona, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…

8 months ago